Adachi Mio, Ishiba Toshiyuki, Maruya Sakiko, Hayashi Kumiko, Kumaki Yuichi, Oda Goshi, Aruga Tomoyuki
Department of Breast surgery, Institute of Science Tokyo, Tokyo, Japan.
Department of Surgery (Breast), Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
JMA J. 2025 Apr 28;8(2):486-497. doi: 10.31662/jmaj.2024-0243. Epub 2025 Feb 14.
Luminal breast cancer is the most common breast cancer subtype. Although its prognosis can be good, this type of breast cancer is characterized by a high incidence of late recurrence. However, to the best of our knowledge, there are no publications showing prognostic value regarding the invasive-disease-free survival (IDFS) and distant relapse-free survival in this group in clinical practice. Therefore, this study examined the clinical data and prognosis of patients participating in the MonarchE trial.
This study included patients who underwent surgery at Tokyo Metropolitan Komagome Hospital and whose corresponding prognosis to the Monarch E trial could be followed up.
The total number of participants was 152, of whom 104 (68%) were treated with chemotherapy. Seventy-five patients (49%) were postmenopausal. The IDFS after 5 years was 85.0%. Although IDFS did not differ in terms of the menstrual status, premenopausal patients tended to receive a higher proportion of tamoxifen, and there was a greater number of patients treated with chemotherapy. However, neither chemotherapy nor menstrual statuses were found to affect the IDFS incidence.
Real clinical data applicable to the MonarchE study were examined. Our univariate analysis revealed that there were no factors affecting IDFS.
管腔型乳腺癌是最常见的乳腺癌亚型。尽管其预后可能良好，但这种类型的乳腺癌具有晚期复发率高的特点。然而，据我们所知，在临床实践中，尚无关于该组患者无侵袭性疾病生存期（IDFS）和无远处复发生存期的预后价值的相关报道。因此，本研究对参与MonarchE试验的患者的临床数据和预后进行了研究。
本研究纳入了在东京都驹込医院接受手术且其预后可在MonarchE试验中得到随访的患者。
参与者总数为152人，其中104人（68%）接受了化疗。75名患者（49%）已绝经。5年后的IDFS为85.0%。尽管IDFS在月经状态方面没有差异，但绝经前患者接受他莫昔芬的比例往往更高，且接受化疗的患者数量更多。然而，未发现化疗和月经状态会影响IDFS发生率。
对适用于MonarchE研究的实际临床数据进行了研究。我们的单因素分析显示，没有影响IDFS的因素。
